Cart
sales@molnova.com
Edralbrutinib
CAS No. 1858206-58-2
Edralbrutinib( —— )
Catalog No. M35710 CAS No. 1858206-58-2
Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity used in treating tumors, immune system disorders, and blood and lymphatic system disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 187 | In Stock |
|
| 10MG | 301 | In Stock |
|
| 25MG | 506 | In Stock |
|
| 50MG | 706 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEdralbrutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEdralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity used in treating tumors, immune system disorders, and blood and lymphatic system disorders.
-
DescriptionEdralbrutinib (TG-1701) is a potent BTK inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1858206-58-2
-
Formula Weight489.47
-
Molecular FormulaC26H21F2N5O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C2=C(C(=CN2[C@H]3CN(C(C#CC)=O)CC3)C4=CC=C(OC5=C(F)C=CC=C5F)C=C4)C(N)=NN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. JIANGSU HENGRUI MEDICINE CO, et al. Pharmaceutically acceptable salt and crystal form of pyrrolo[2,3-d]pyridazin-7-one derivative and preparation method of medicinal salt and crystal form. WO2018210296A1.
molnova catalog
related products
-
BGB-8035
BGB-8035 is an orally available, selective and potent BTK inhibitor with antitumor activity that inhibits BTK, TEC and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.
-
ARQ-531
ARQ-531 (ARQ531) is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, respectively.
-
Atuzabrutinib
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
